Helen Ebert1, Maria Elena Lacruz2, Alexander Kluttig3, Andreas Simm4, Karin Halina Greiser5, Daniel Tiller6, Nadja Kartschmit7, Rafael Mikolajczyk8. 1. Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Germany. Electronic address: helen.ebert@student.uni-halle.de. 2. Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Germany. Electronic address: elena.lacruz.dediego@gmail.com. 3. Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Germany. Electronic address: alexander.kluttig@medizin.uni-halle.de. 4. University Clinic and Outpatient Clinic for Cardiac Surgery, Middle German Heart Centre at the University Hospital Halle, Germany. Electronic address: andreas.simm@uk-halle.de. 5. Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Germany; German Cancer Research Center DKFZ (Deutsches Krebsforschungszentrum), Heidelberg, Germany. Electronic address: h.greiser@dkfz-heidelberg.de. 6. Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Germany. Electronic address: daniel.tiller@medizin.uni-halle.de. 7. Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Germany. Electronic address: nadja.kartschmit@uk-halle.de. 8. Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Germany. Electronic address: rafael.mikolajczyk@medizin.uni-halle.de.
Abstract
BACKGROUND: Advanced glycation end products (AGEs) in the plasma are associated with a number of age-related diseases that possibly lead to reduced longevity. However, previous studies showed large inconsistencies in the association between AGEs or their soluble receptor (sRAGE) and mortality. We studied this association in a cohort study of general population and assessed the potential changes in this association over time. METHODS: We used data of 958 men and 802 women from the general population in Halle, Germany with a follow up of 12 years. The associations were assessed by means of Kaplan-Meyer survival curves and multivariable and time-varying Cox-regression. RESULTS: AGEs and sRAGE were either not or only weakly (and in the other direction than expected) associated with all-cause mortality after 12 years follow-up in men and women (AGEs: Hazard ratio (HR) = 0.93, 95% confidence interval (95%CI) = 0.83-1.05 for men; HR = 0.88, 95%CI = 0.74-1.05 for women; sRAGE: HR = 1.08, 95%CI = 0.95-1.23 for men; HR = 1.10, 95%CI = 0.92-1.30 for women). There was no change of the predictive values over the follow up time. Sub-analyses with participants with and without AGEs-related conditions (diabetes mellitus and decreased renal function), with age stratified groups (younger (<65 years) and older (≥65 years) participants), with cardiovascular disease mortality as the outcome and the AGE/sRAGE ratio as predictor provided similar results. CONCLUSIONS: Our findings suggest a lack of the expected association with mortality and contribute to the inconsistent findings for plasma-measured AGEs, sRAGE, and AGE/sRAGE ratio.
BACKGROUND: Advanced glycation end products (AGEs) in the plasma are associated with a number of age-related diseases that possibly lead to reduced longevity. However, previous studies showed large inconsistencies in the association between AGEs or their soluble receptor (sRAGE) and mortality. We studied this association in a cohort study of general population and assessed the potential changes in this association over time. METHODS: We used data of 958 men and 802 women from the general population in Halle, Germany with a follow up of 12 years. The associations were assessed by means of Kaplan-Meyer survival curves and multivariable and time-varying Cox-regression. RESULTS: AGEs and sRAGE were either not or only weakly (and in the other direction than expected) associated with all-cause mortality after 12 years follow-up in men and women (AGEs: Hazard ratio (HR) = 0.93, 95% confidence interval (95%CI) = 0.83-1.05 for men; HR = 0.88, 95%CI = 0.74-1.05 for women; sRAGE: HR = 1.08, 95%CI = 0.95-1.23 for men; HR = 1.10, 95%CI = 0.92-1.30 for women). There was no change of the predictive values over the follow up time. Sub-analyses with participants with and without AGEs-related conditions (diabetes mellitus and decreased renal function), with age stratified groups (younger (<65 years) and older (≥65 years) participants), with cardiovascular disease mortality as the outcome and the AGE/sRAGE ratio as predictor provided similar results. CONCLUSIONS: Our findings suggest a lack of the expected association with mortality and contribute to the inconsistent findings for plasma-measured AGEs, sRAGE, and AGE/sRAGE ratio.
Authors: Katarína Šebeková; Radana Gurecká; Melinda Csongová; Ivana Koborová; Jozef Šebek Journal: Int J Environ Res Public Health Date: 2020-05-21 Impact factor: 3.390
Authors: Lamiaa Hassan; Ljupcho Efremov; Anne Großkopf; Alexander Kluttig; Rafael Mikolajczyk; Nadja Kartschmit; Daniel Medenwald; Artjom Schott; Andrea Schmidt-Pokrzywniak; Maria E Lacruz; Daniel Tiller; Frank Bernhard Kraus; Karin H Greiser; Johannes Haerting; Karl Werdan; Daniel Sedding; Andreas Simm; Sebastian Nuding Journal: Eur J Epidemiol Date: 2022-01-03 Impact factor: 8.082
Authors: Komal Waqas; Jinluan Chen; Fernando Rivadeneira; André G Uitterlinden; Trudy Voortman; M Carola Zillikens Journal: J Gerontol A Biol Sci Med Sci Date: 2022-10-06 Impact factor: 6.591